-
2023-503699-25-00
5
2024-07-15
Progressive Pulmonary Fibrosis
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2023-503904-10-00
5
2024-06-07
Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity
-
2022-502405-15-01
4
2024-04-08
Mantle Cell Lymphoma (MCL)
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2022-501599-25-00
5
2024-03-19
juvenile idiopathic arthritis
-
2022-502286-16-00
5
2023-10-27
Primary Generalized Tonic-Clonic Seizures
-
2022-500266-10-00
5
2023-06-13
Recessive Dystrophic Epidermolysis Bullosa(RDEB) and Junctional Epider
-
2022-500544-38-00
5
2023-06-05
Advanced Breast Cancer
-
2023-509810-13-00
4
2023-05-13
Acute Lymphoblastic Leukemia (ALL)
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2022-500367-12-00
5
2022-11-30
Dermatomyositis
-
2022-500461-28-06
5
2022-09-15
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-511686-11-00
5
2021-10-05
Multiple Sclerosis in pediatric patients
-
2024-512657-24-00
10
2014-03-27
Acute Lymphoblastic Leukaemia
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis
-
2025-523079-44-00
5
2026-04-15
Turner Syndrome (TS)
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2025-522403-17-00
5
2026-04-10
Nummular Dermatitis